Growth Hormone Deficiency in Kids: When to Seek Testing and Diagnosis
When a child isn’t growing as expected, it’s easy to chalk it up to genetics or a late growth spurt. But sometimes slow growth has an underlying medical cause — one that is both diagnosable and treatable. Pediatric growth hormone deficiency (GHD) affects an estimated 1 in 4,000 to 1 in 10,000 children, and for many families, getting to a diagnosis takes longer than it should.
One reason for that delay may have less to do with biology than with bias. Bias is when someone favors one person or group over another, not because of facts or evidence, but because of assumptions, stereotypes, or personal beliefs. It can affect how people are treated, even when the person being biased doesn’t realize they’re doing it.
What Is Pediatric GHD?
GHD occurs when the pituitary gland — a small gland at the base of the brain — doesn’t produce enough growth hormone. Growth hormone is critical not just for height, but for bone density, muscle development, and metabolism. Without enough of it, a child’s body can’t grow and develop at a normal rate.
The condition can be present from birth or develop later due to a brain injury, tumor, radiation treatment, or sometimes with no identifiable cause at all. Regardless of origin, the effect is the same: a persistent pattern of slow or stalled growth that warrants medical attention.
Signs to Watch For
Short stature alone isn’t a diagnosis, but certain patterns should prompt a closer look. Children with GHD typically grow less than 2 inches per year after age 3 and may fall at or below the 3rd percentile on growth charts consistently over time. They may also appear younger than peers, experience delayed puberty, or show lower energy and muscle tone than expected for their age.
The key is pattern over time: a consistent trajectory of lagging behind, not a single snapshot.
A Diagnostic Gap That Affects Many Children
GHD occurs across all children regardless of gender, but not all children are being diagnosed equally. Research consistently shows that children assigned male at birth are referred for short stature evaluation and growth hormone testing at roughly twice the rate of children assigned female at birth. In major growth hormone surveillance programs, males have made up around 70% of children diagnosed and treated for GHD.
This gap doesn’t reflect biology. It reflects perception.
The underdiagnosis of female children is tied to a widespread societal assumption that it’s acceptable for them to be short or “petite.” When parents and providers consider the impact of short stature, research shows they are far more likely to view it as a meaningful concern in male children — affecting self-esteem and future success — while dismissing the same issue in female children.
That assumption has real consequences. Studies have found that when female children are finally referred and tested, they tend to be significantly shorter at the time of diagnosis — meaning they waited longer, lost more time, and had fewer years to benefit from treatment. Every child deserves the same access to evaluation, regardless of gender identity or the assumptions others may hold.
Why Early Evaluation Matters
GHD is treatable, and children identified early have the most to gain. Delayed diagnosis narrows the critical window of childhood growth, and for children who are already being referred later and at shorter heights due to bias, that delay compounds the disadvantage.
Diagnosis typically involves growth chart tracking over time, bone age X-rays, blood tests, and growth hormone stimulation testing. A pediatrician is the right starting point and can refer families to a pediatric endocrinologist when GHD is suspected.
Talk to Your Pediatrician — For Every Child
If your child seems to be falling behind on growth, bring it up at your next well-child visit. No child’s growth concerns should be dismissed based on assumptions about gender or how they identify.